Searchable abstracts of presentations at key conferences in endocrinology

ea0099rc4.5 | Rapid Communications 4: Diabetes, Obesity, Metabolism and Nutrition | Part I | ECE2024

Precision medicine in type 2 diabetes mellitus: Unraveling the role of TCF7L2, CTRB1/2, and GLP-1R genetic variants in response to treatment with glucagon-like peptide-1 receptor agonists

Kyriakidou Artemis , Kyriazou Angeliki , Koufakis Theocharis , Vasilopoulos Yiannis , Avramidis Iakovos , Baltagiannis Stefanos , Goulis Dimitrios , Zebekakis Pantelis , Kotsa Kalliopi

Background and Aims: Our objective was to assess the association between genetic polymorphisms in TCF7L2, CTRB1/2 and GLP-1R genes and inter-individual variability in response to treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in terms of glycemic control and weight loss among Greek individuals with type 2 diabetes mellitus (T2DM) and to identify potential predictors of response to GLP-1 RA therapy.Material...

ea0081p579 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

Association between clinical and genetic factors and glycemic and weight loss response to liraglutide in patients with type 2 diabetes

Kyriakidou Artemis , Kyriazou Angeliki V. , Koufakis Theocharis , Vasilopoulos Yiannis , Grammatiki Maria , Mellidou Eirini , RAKITZI PANTELITSA , Karaliolios Georgios , Goulis Dimitrios , Zebekakis Pantelis , Kotsa Kalliopi

Background: Previous research suggests an association between specific genetic variations and interindividual variability in response to treatment with glucagon-like receptor agonists (GLP-1 RAs) in patients with type 2 diabetes mellitus (T2DM). We aimed to evaluate the role of CTRB1/2 rs7202877 (T>G) polymorphism in glycemic control and weight loss response to liraglutide among Greek patients with T2DM and to identify clinical factors related to prediction of res...